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Rhizomelic chondrodysplasia punctataPeroxisomal disorders are an important group of neurometabolic diseases. The clinical presentation is varied in
terms of age of onset, severity, and different neurological symptoms. The clinical course spans fromdeath in infancy,
rapid functional decline, slow decline on long-term followup, to apparent stable course. Leukoencephalopathy and
developmental anomalies are characteristic ﬁndings on cerebral MR imaging. From a diagnostic point of view the
disorders can be clinically subdivided into four broad categories: (1) the Zellweger spectrum disorders and the
peroxisomal ß-oxidation disorders, (2) the rhizomelic chondrodysplasia punctata spectrum disorders, (3) the
X-linked adrenoleukodystrophy/adrenomyeloneuropathy complex and (4) the remaining disorders. This article
discusses the role of MRI ﬁndings in the clinical approach of peroxisomal disorders with neurological disease. This
article is part of a Special Issue entitled: Metabolic Functions and Biogenesis of peroxisomes in Health and Disease.
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Peroxisomal disorders are a heterogeneous group of inborn errors
of metabolism that result in impairment of peroxisome function [1].
In most cases, this results in neurologic dysfunction of varying extent.
The peroxisome incorporates a set of substrate-speciﬁc metabolic
pathways, which have a role in the formation and functioning of the
nervous system. Disorders of peroxisome function are divided into
two major categories. The ﬁrst are diseases resulting from a failure
in organelle formation, giving rise to multiple metabolic abnormali-
ties. This group is named Peroxisome Biogenesis Disorders (PBD),
which can be divided into two subtypes, including: (1) the Zellweger
spectrum disorders (ZSDs) and (2) the rhizomelic chondrodysplasia
punctata (RCDP) type 1. The second category includes the disorders,
which result from the deﬁciency of a single peroxisomal enzyme or
transporter. Table 1 presents the classes of peroxisomal disorders.
The ZSDs are a continuum of at least three phenotypes—Zellweger
syndrome (ZS), the most severe; neonatal adrenoleukodystrophy
(NALD); and infantile Refsum disease (IRD), the least severe—that
were originally described before the biochemical and molecular
bases of the disorders had been determined (Table 1 and 2).lic Functions and Biogenesis of
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rights reserved.Patients with a single peroxisomal ß-oxidation enzyme defect at the
level of acyl-CoA oxidase 1 or D-bifunctional protein present very
similar clinical manifestations as those seen in ZSDs. Therefore, clini-
cally these disorders can be discussed as one group. Patients with
ZSDs present with a plethora of manifestations, in particular common
to all three phenotypes are liver disease, variable neurodevelopmental
delay, retinopathy and sensorineural deafness.
RCDP type 1 is a PBD different from ZSDs but clinically not distin-
guishable from RCDP types 2 and 3. RCDP types 2 and 3 are caused by
isolated deﬁciencies of one of the peroxisomal enzymes involved in
the biosynthesis of plasmalogens [2]. The name RCDP spectrum has
been proposed for this distinct peroxisomal entity including its milder
variants. Patients with a RCDP spectrum have a skeletal dysplasia
including proximal shortening of the limbs (rhizomelia) and punctate
calciﬁcations in cartilage present at birth, profound growth deﬁciency,
cataracts and severe psychomotor defects [3]. A milder phenotype has
chondrodysplasia without rhizomelia, cataracts, and less severe growth
and mental deﬁciency.
The clinical presentation of X-linked adrenoleukodystrophy (ALD)/
adrenomyeloneuropathy (AMN) is different from the other peroxisom-
al disorders [4]. Three main phenotypes are recognized in affected
males including the severe childhood cerebral ALD (CCALD), adult
AMN and Addison disease only. Females who are carriers may develop
neurologic manifestations that resemble AMN. Patients with Refsum
disease present retinitis pigmentosa and a variable combination of
ataxia, neuropathy, deafness, and ichthyosis.
The clinical presentation in patients, affected by α-methylacyl-
CoA racemase (AMACR) deﬁciency has some resemblance to that of
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failure or with stroke-like episodes and/or recurrent rhabdomyolysis.
As in other neurometabolic disorders the diagnosis of peroxisomal
diseases is based on clinical features and family history followed by a
battery of biochemical analyses in blood that are then conﬁrmed in
cultured ﬁbroblasts and by molecular genetic testing. Differential
diagnosis varies with the age of presentation and most prominent
features of presentation. In this context neuroimaging ﬁndings are a
valuable feature in the differential diagnosis [6]. Not only the well-
known MRI pattern of CCALD is a crucial clue for the right diagnosis,
but also characteristic MRI patterns for ZSDs, RCDP and peroxisomal
ß-oxidation disorders can be of great value for the diagnosis.
This article focuses on the peroxisomal disorders with neurological
disease and the spectrum of MRI ﬁndings in these disorders.
2. Clinical phenotypes and cerebral MRI spectrum
2.1. Zellweger spectrum disorders (ZSDs)
When the group of patients suffering from a disorder of peroxisome
biogenesis is taken together, roughly three proﬁles can be distinguished
which should warrant detailed biochemical investigations [7,8].
These include:
1. A neonatal proﬁle, essentially involving: a. severe muscular hypoto-
nia with resultant poor feeding, b. seizures, c. hepatic dysfunction
including mixed hyperbilirubinemic jaundice, and d. dysmorphic
signs.
2. A childhood proﬁle, essentially involving: a. retinopathy often leading
to early blindness, b. sensorineural deafness, c. hepatic dysfunction
that may involve symptoms of vitamin K-responsive coagulopathy,
d. developmental delay, e. (often) failure to thrive, f. dysmorphic
signs, g. adrenal insufﬁciency.
3. A late-onset mild proﬁle, essentially involving: a. cerebellar ataxia,
b. neuropathy, c. sensorineural deafness, d. retinopathy, e. cholestatic
liver disease during infancy.
Bony changes in the neonatal and childhood group, involve a large
fontanel which only closes after the ﬁrst birthday, osteopenia of long
bones, and, in approximately half of the cases, calciﬁed stippling in the
epiphyseal and periarticular regions of large joints, especially the patel-
lar region. Cerebral abnormalities in the neonatal and childhood groups
essentially comprise two sets of abnormalities, namely neocortical dys-
genesis, due to neuronal migration failure arising during the embryo-Table 1
Classiﬁcation of peroxisomal disorders with nervous system involvement.
Disorder Abbreviation
Disorders of peroxisome biogenesis
–Zellweger spectrum disorders ZSD, PBD,
–Zellweger syndrome ZS
–Neonatal adrenoleukodystrophy NALD
–Infantile Refsum disease IRD
Rhizomelic chondrodysplasia punctata type 1 RCDP1
Single peroxisomal enzyme/protein deﬁciencies
X-linked adrenoleukodystrophy and adrenomyeloneuropathy XALD
AMN
Peroxisomal acyl-CoA oxidase 1 deﬁciency ACOX1D
D-bifunctional protein deﬁciency DBPD
Rhizomelic chondrodysplasia punctata type 2 RCDP2
Rhizomelic chondrodysplasia punctata type 3 RCDP3
Refsum disease RD
2-Methylacyl-CoA racemase deﬁciency AMACRD
DHAPAT, dihydroxyacetone phosphase acyltransferasefetal period and metabolic changes involving the process of myelina-
tion, and in some cases leading to later demyelination. To name a partic-
ular proﬁle of ZSDs might be useful when discussing prognosis and
counseling families but one should not place too much emphasis to
these subtypes.
Patients with ZS are severely hypotonic and weak from birth on,
have distinct facial features, have retinopathy and deafness with onset
in the ﬁrst months of life, severe brain dysfunction associated with
neuronal migration disorder, and rarely survive the ﬁrst year of life. In
classic ZS neocortical dysplasia is well depicted by MRI, especially a
very characteristic perisylvian polymicrogyria, which appears as a
thickened cortical mantle [9] (Fig. 1). There is a general decrease in
the volume of thewhitematter, delayedmyelination, and bilateral ven-
tricular dilatation as common nonspeciﬁc ﬁndings in ZS. Germinolytic
cysts are often seen in these patients. Patients with neonatal adrenoleu-
kodystrophy (NALD) have an early onset progressive leukodystrophy,
may have polymicrogyria in the area of the Sylvian ﬁssure, retinopathy
and deafness,mostly nodistinctive facial features, and usually die in late
infancy [10]. The progressive demyelination in NALD is diffuse and
affects cerebral (Fig. 2) and cerebellar hemispheres with involving
both the hilus of the dentate nucleus and the peridentate white matter.
Patients with Infantile Refsum disease (IRD) may have external features
reminiscent of Zellweger syndrome such as Down syndrome-like facies.
Most often they have no obvious facial dysmorphia. They have no
neuronal migration disorder, and are supposed not to have progressive
white matter disease. The clinical course is variable [11]. Their cognitive
and motor development varies between severe handicap and moderate
learning disorderwith deafness and visual impairment related to retinop-
athy. Occasionally, symptoms are very subtle which may delay diagnosis
until late childhood or adulthood.Most patientswith IRD reach childhood
and some even reach adulthood. MRI is normal in some patients. Howev-
er, progressive leukoencephalopathy may occur also in IRD following
apparently a stable neurologic symptomatology [12]. This pathology
seems to be related to a prolonged course of disease (Fig. 3). MR
images may show involved areas including the corpus callosum, areas
surrounding the lateral ventricles, internal capsules, peridentate white
matter, brainstem, and central white matter of cerebellar hemispheres.
Comparison of clinically silent leukoencephalopathy to symptomatic
leukoencephalopathy reveals similarity in distribution of white matter
lesions including the peridentate white matter as an early focus.
The so called late onset whitematter disease is a distinct phenotype in
ZSD [13]. These patients have an almost normal early development
during the ﬁrst year and no distinctive features. Patients may alsoGene symbol Enzyme deﬁciency Associated phenotypes
Multiple Generalized Zellweger spectrum
PEX genes
PEX7 DHAPAT RCDP and variants
Alkyl-DHAP synthase
Phytanoyl CoA hydroxylase
ABCD1 ABC transporter protein XALD, XAMN, and variants
Peroxisomal acyl-CoA NALD-like disease
oxidase 1
HSD17B4 D-bifunctional protein ZS-like disease
GNPAT Dihydroxyacetone RCDP and variants
phosphate acyltransferase
AGPS Alkyl-DHAP synthase RCDP and variants
PHYH Phytanoyl-CoA hydroxylase Refsum disease
AMACR AMACR Adult-onset polyneuropathy
Table 2
Biochemical characteristics of different peroxisomal disorders.
Diagnostic group
1 2 3 4
ZSDs
(ZS, NALD, IRD)
ACOX1D DBPD RCDP RCDP RCDP X-ALD RD AMACRD
Type 1 Type 2 Type 3
Plasma
Very-long chain fatty acids ↑ ↑ ↑ N N N ↑ N N
Di- and trihydroxy-cholestanoic acid ↑ N ↑a N N N N N ↑
Phytanic acid N-↑b N N-↑d N-↑b N N N ↑ N-↑
Pristanic acid N-↑ N N-↑c N N N N N ↑
Erythrocyte membranes
Plasmalogen level ↓ N N ↓ ↓ ↓ N N N
Fibroblasts
Plasmalogen synthesis ↓ N N ↓ ↓ ↓ N N N
DHAPAT ↓ N N ↓ ↓ ↓d N N N
Alkyl DHAP synthase ↓ N N ↓ N ↓ N N N
C26:0 ß-oxidation ↓ ↓ ↓ N N N ↓ N N
Pristanic acid ß-oxidation ↓ N ↓ N N N N N ↓
Acyl-CoA oxidase 1 ↓ ↓ N N N N N N N
D-bifunctinoal protein ↓ N ↓ N N N N N N
Phytanic acid α-oxidation ↓ N N ↓ N N N ↓ N
Phytanoyl CoA hydroxylase ↓ N N ↓ N N N ↓ N
Peroxisomes Absent Present but abnormal Present but abnormal Present Present Present Present Present Present
ZSDs, Zellweger spectrum disorders; ZS, Zellweger syndrome; NALD, neonatal adrenoleukodystrophy; IRD, infantile Refsum disease; AOXD, acyl-CoA oxidase 1 deﬁciency; DBPD, D-
bifunctional protein deﬁciency; RCDP, rhizomelic chondrodysplasia punctata; X-ALD, X-linked adrenoleukodystrophy; RD, Refsum disease; AMACRD, 2-methylacyl-CoA racemase
deﬁciency; N, normal; NK, not known.
a Di- and trihydroxycholestanoic acid are not elevated in all DBPD-patients.
b Phytanic acid is derived from dietary sources only and may therefore vary from normal to elevated in patients in whom phytanic acid α-oxidation is deﬁcient.
c Pristanic acid is derived from dietary sources only either directly or indirectly from phytanic acid via α-oxidation and may therefore vary from normal to elevated if pristanic
acid β-oxidation is deﬁcient.
d Phytanic acid is often elevated if pristanic acid β-oxidation is impaired even if phytanic acid β-oxidation per se is normal.
Fig. 1. Coronal T2-weighted image of a neonate with classical ZS. It reveals the characteristic
perisylvian polymicrogyria, which appears as a thickened cortical mantle.
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onset of moderate delay in mental and motor development in the ﬁrst
months of life. These patients differ from “classic” IRDby the precipitous
neurologic regression in late infancy, in adolescence or adulthood with
associated cerebral white matter disease. In all patients with “late onset
whitematter disease” the rapid deterioration includes severe hypotonic
pareses, seizures, retinopathy, and sensory deafness. MRI in all
patients shows cerebral demyelination (predominantly in the centrum
semiovale) with sparing of subcortical ﬁbres and pronounced central
cerebellar white matter involvement (Fig. 4). The reason for the late
onset of regressive white matter disease in generalized peroxisomal
disorders is unknown. Diffusion-weighted imaging and diffusion tensor
imaging may be helpful to discern white matter abnormalities not
detected by standard imaging [14].
To deﬁne neuroimaging characteristics of 25 ZSD patients with pro-
longed (surviving the ﬁrst year) survival, Barth et al. delineated three
major patterns of abnormalities: (1) normal images, (2) developmental
anomalies with subgroups in this category, including neocortical
dysplasia andmild to moderate dilatation of parts or the whole ventricu-
lar system, and (3) regressive changes with two subgroups of leukoence-
phalopthy [12]. There is a subgroupwith supratentorial and infratentorial
involvement of white matter without signs of neurologic deterioration,
except for slow motor and cognitive decline on long-term follow-up.
The subgroup with clinically progressive leukoencephalopathy presents
rapid functional decline and neurologic symptoms. Comparison of clini-
cally silent leukoencephalopathy to symptomatic leukoencephalopathy
reveals similarity in distribution of white matter lesions. A relationship
between the degree of leukoencephalopathy and the associated PEX
mutations could not be established. Weller et al. observed less frequently
leukoencephalopathy compared with the report of Barth et al., which
might be related to the younger age of their patients [15]
Cerebellar atrophy without concomitant supratentorial atrophy In
mild ZSDs with ataxia may constitute an additional distinct subgroup
whichbroadens the spectrumof presentations in peroxisomal disorders
[16,17].2.2. The peroxisomal ß-oxidation disorders
Four deﬁned disorders of peroxisomal very long chain fatty acids ß-
oxidation have been identiﬁed including: (1) peroxisomal acyl-CoA
oxidase 1 deﬁciency, (2) D-bifunctional protein deﬁciency, (3) peroxi-
somal thiolase deﬁciency and (4) X-linked adrenoleukodystrophy/
adrenomyeloneuropathy. The clinical presentation of the disorders 1
Fig. 2. NALD patient at age 2.5 years. Axial T1-weighted MR image shows severe involve-
ment of cerebral white matter.
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the clinical presentation of X-linked ALD/AMN patients is different
which explains why this entity is discussed separately.Fig. 3. Patientwith Zellweger spectrumdisorder at age of 14.5 years. Axial spin-echo T2-weight
ventricles and signal increase in the splenium and genu of the corpus callosum and in the bilate
the dentate nucleus, with the spared dentate nucleus in between (B).Peroxisomal thiolase 2 deﬁciency, also named sterol carrier protein
X deﬁciency, has so far been described in only a single 45-year-old
patient [18].
Peroxisomal acyl-CoA oxidase1 deﬁciency was ﬁrst described under
the name pseudo-neonatal adrenoleukodystrophy since the 2 patients
described had the typical signs and symptoms described for neonatal
adrenoleukodystrophy [19]. However, peroxisomes were present in
the patients' liver and even of enlarged size. In addition, tri- and
dihydroxy-cholestanoic acid (THCA and DHCA) were completely
normal. The disease has its onset in the neonatal period with muscular
hypotonia and seizures. Patients may achieve walking and learn to
speak a few words before neurologic deterioration sets in, usually at
the age of 1 to 3 years. MRI performed at birth may be normal,
but soon after the onset of neurologic deterioration the MRI shows
progressive white matter changes [20].
D-bifunctional protein (DBP) deﬁciency, the second peroxisomal ß-
oxidation disorder, has usually a severe neurologic presentation similar
to that in ZS with neonatal hypotonia, seizures and hepatomegaly, and
not surviving the age of 2 years [21,22]. A minority have a prolonged
survival. Remarkably, some patients were identiﬁed without biochemical
abnormalities in plasmaor serum, stressing that DBPdeﬁciency cannot be
excluded when all peroxisomal blood parameters are normal [23].
MRI studies present in some but not all patients developmental
abnormalities including neocortical dysplasia (especially perisylvian
polymicrogyria) similar to that often found in ZS, as well as a cerebral
and cerebellar demyelination. Ferdinandusse et al. described the results
of a study in a large cohort of 126 DBP patients and concluded that
there is a clear correlation between several biochemical parameters and
survival of the patients, with C26:0 ß-oxidation activity in cultures skin
ﬁbroblasts being the best predictive marker for life expectancy [22].
Using an exome sequencing approach, Pierce et al. [24] reported
mutations in HSD17B4 in two sisters affected by Perrault syndrome, a
condition characterized by ovarium dysgenesis and hearing loss inedMR images show: bilateral areas of signal increase surrounding posterior parts of lateral
ral internal capsules (A), signal increase in the central cerebellar area including the hilus of
Fig. 4. Patient with “late onset” white matter disease, similar to NALD but starting at a later age, at age 3 months with normal axial T2-weighted images (A,B) and at age 2.5 years with
cerebral demyelination affecting frontal and posterior parts of periventrucular white matter (C), central parts of cerebellar hemispheres and hilar region of the dentate nucleus (D).
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mutations cause DBP deﬁciency. The lack of mutations in eight other
Perrault families provides evidence for a genetic heterogeneity of this
syndrome [25].
X-linked adrenoleukodystrophy (X-ALD)/adrenomyeloneuropathy
(AMN)) X-ALD and AMN are clinically distinct from the other two
single enzyme deﬁciencies of peroxisomal ß-oxidation, and the
biochemical ﬁnding of an increase in plasma of very long chain fatty
acids (VLCFA) concentration is a reliable diagnostic marker.
The symptoms of X-ALD are highly variable and unpredictable [4].
X-ALD should be considered as a cause of Addison's disease in boys,adolescents and adult males. Childhood X-ALD most frequently
presents as “childhood cerebral ALD” (CCALD), most often in early
school age. The onset of CCALD is insidious, with hyperactive behavior
and declining school performance. As the disease progresses, more
overt neurological deﬁcits become apparent, including central deafness,
decreased visual acuity, spastic tetraparesis, cognitive decline and
seizures leading to a severe disability and death within years after
onset of symptoms. Typically, the initial lesions are localized in the
splenium of the corpus callosum and progress to involve the parieto-
occipital white matter. The frontal, parietal or asymmetrical variant of
cerebral X-ALD is seen less frequently [6,26]. On MRI the areas affected
Fig. 5. Axial T2-weighted image of a patient with an adult onset cerebral X-ALD at age
35 years with lesions in the splenium of the corpus callosum and parieto-occipital white
matter on T2-weighted image.
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The border of the lesion enhances after administration of gadolinium,
reﬂecting the marked inﬂammatory reaction that is typical in this
disorder.
Although less frequently, cerebral demyelination can also occur in
adolescence (AdolCALD) or adulthood (ACALD) [27]. The symptomatol-
ogy and disease progression in these patients strongly resembles CCALD
(Fig. 5). Virtually all patients with X-ALD who reach adulthood develop
AMN, usually between the third and fourth decade. Patients develop a
gradually progressive spastic paraparesis, sensory ataxia with impaired
vibration sense, sphincter dysfunction, pain in the legs and impotence.
TheMRI of the spinal cord is unremarkable on standardMRI sequences,
but can show atrophy in advanced cases [28]. As is the case in many
X-linked diseases, it was assumed that female carriers remain asymp-
tomatic. However, it is now clear that many women develop AMN-
like symptoms [29]
2.3. Rhizomelic chondrodysplasia punctata (RCDP) spectrum types 1, 2 and 3
The diagnosis of RCDP is based on highly speciﬁc clinical ﬁndings
and conﬁrmed by biochemical or molecular genetic testing. The classic
prototype of RCDP is characterized by symmetric proximal shortening
of the extremities (rhizomelia), severe contractures from birth, typical
facial appearance, cataracts that are usually present at birth or appear
in the ﬁrst months of live, severe growth retardation, and absence of
signiﬁcant development [3]. Biochemical abnormalities include im-
paired plasmalogen biosynthesis in all forms of RCDP and accumulation
of phytanic acid (diet dependent) in RCDP type 1, RCDP type 1 is caused
by a defect in the PEX7, which encodes the peroxisome targeting signal
(PTS) 2 receptor. The PTS2 receptor plays a key role for a subset of per-
oxisomal matrix enzymes [2]. A minority of patients with RCDP type 1
has a milder clinical and biochemical phenotype, with all congenital
cataracts and skeletal dysplasia, but without rhizomelia, less severe
neurologic impairment, and less severe mental and growth deﬁciency
[30,31]. Clinically the classic RCDP type 1 phenotype is indistinguishable
to that of patients with isolated deﬁciencies of either of two peroxisom-
al enzymes involved in plasmalogen biosynthesis. RCDP type 2 is caused
by deﬁciency of the dihydroxyacetone phosphate acyltransferase
(DHAPAT). RCDP type 3 is caused by deﬁciency of the enzyme alkyl-
DHAP synthase (ADHPS) [1]
The severe phenotype of RCDP is accompanied by a speciﬁc pattern
of both developmental and regressive MRI abnormalities including
delay in supratentorial white matter myelination and white matter
signal abnormalities not related to delay in myelination, particularly
the parieto-occipital region (Fig. 6). Progressive cerebellar atrophy
may also be an MRI feature of the severe type of RCDP [32,33].
2.4. The remaining disorders
2.4.1. Refsum disease
Characteristic manifestations of the disease include early-onset
retinitis pigmentosa and variable combinations of cerebellar ataxia,
polyneuropathy, and an elevated cerebrospinal ﬂuid (CSF) protein
level. Less constant features include sensorineural hearing loss, anos-
mia, ichthyosis, skeletal malformations, and cardiac abnormalities. Not
all patients develop all the symptoms of Refsum disease and in some
patients it is limited to retinitis pigmentosa. Most patients present the
clinical picture of a slowly developing retinopathy, and progressive
peripheral neuropathy manifested by severe motor weakness and
muscular wasting, especially of the lower extremities. Exacerbations
may occur with acute illness, fasting, rapid weight loss, andwhen preg-
nant. Most patients have clear-cut manifestations before 20 years of
age. Onset has occasionally been detected in early childhood and in
the ﬁfth decade in others. Patients with Refsum disease may die
suddenly probably from cardiac arrhythmias and heart failure caused
by cardiomyopathy [34]. Manifestations of Refsum disease may varyconsiderably, also within family. To our knowledge neither CT nor
MRI ﬁndings have been published so far. Our MRI ﬁnding of a 52 years
old Refsum patient was that of a mild generalized cerebral atrophy
without white matter abnormalities.
2.4.2. α-Methylacyl-CoA racemase (AMACR) deﬁciency
This rare peroxisomal disorder was ﬁrst described in two patients
suffering from an adult-onset sensorimotor neuropathy with or
without associated pigmentary retinopathy [5]. The enzyme involved
catalyzes the interconversion of (2R)- and-(2S)-stereoisomers of
α-methylbranched-chain fatty acids like pristanic acid, THCA and
DHCA whereas this enzyme is not involved in VLCFA ß-oxidation,
which explains the accumulation of THCA, DHCA and pristanic acid
but not C26:0 in these patients. The clinical picture has some resem-
blance to that of Refsum disease with sensorimotor neuropathy.
Other patients presented liver failure very early in life [35], recurrent
rhabdomyolysis [36], depression, cerebellar ataxia, epilepsy and/or
relapsing encephalopathy [37–39]. Various MRI abnormalities have
been reported including cerebral atrophy and hyperintensities on
T2-weighted images in the white matter of both hemispheres, thala-
mi, midbrain, and pons.
2.4.3. Peroxisomal sterol carrier protein X (SCPx) deﬁciency
The patient reportedwith a peroxisomal SCPxdeﬁciency is a 45-year
old man who presented with dystonia, a predominant motor neuropa-
thy, leukoencephalopathy and cerebellar ataxia [18]. Similar to some
AMACR-deﬁcient patients, the patient with SCPx deﬁciency showed
hyperintensities in the thalamus and pons on brain MRI [37–39]
3. Biochemical phenotypes and diagnosis
From a clinical diagnostic point of view peroxisomal disorders
can be subdivided into the following distinct categories including:
(1) the peroxisome biogenesis disorders (PBD)with generalized perox-
isomal dysfunction and the single peroxisomal ß-oxidation disorders
(SPOD), ACOX 1 deﬁciency and DBP deﬁciency, (2) the rhizomelic
Fig. 6. Rhizomelic chondrodysplasia punctata. Axial T2-weighted image at 1.5 years
shows supratentorial white matter signal abnormalities.
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and (4) the remaining disorders.
3.1. PBD and SPOD
Comprehensive biochemical evaluation can distinguish PBD from
peroxisomal acyl-CoA oxidase 1 deﬁciency and D-BP deﬁciency while
the clinical phenotype is overlapping. When a patient is suspected to
be affected by a PBD and SPOD, the ﬁrst analysis to be made is analysis
of VLCFAs. If plasma concentrations are elevated, it is clear that the pa-
tient is either affected by a PBD or SPOD. If plasma concentrations are
normal, a PBD or SPOD is virtually excluded although exceptions have
been published [22,23,40]. If VLCFAs have been found to be abnormal,
plasmalogen levels should be measured in erythrocytes. If plasmalo-
gens are decreased, a PBD is established. If plasmalogens are normal,
however, it probably is a SPOD but it may also be a milder form of
PBD in which plasmalogens may be completely normal in erythrocytes.
In addition to the measurement of plasmalogens, the levels of the
peroxisomal bile acids (THCA and DHCA), pipecolic acid, phytanic acid
and pristanic acidmay also help to reach the correct diagnosis. It should
be noted that some PBD patients with late onset may have normal or
borderline plasma VLCFA and erythrocyte plasmalogen levels, but
abnormal concentrations of plasma phytanic acid, pristanic acid and
peroxisomal bile acid intermediates (personal communication). Excep-
tionally, affected individuals demonstrate normal results of the battery
of biochemical analyses commonly used to diagnose PBD. To establish
the diagnosis, biochemical abnormalities detected in blood and/or
urine should be conﬁrmed in cultured ﬁbroblasts since a detailed
analysis in ﬁbroblasts is essential to ascertain whether peroxisome
biogenesis is primarily affected or whether there is a single enzyme de-
ﬁciency. If a PBD has been established, complementation analysis can be
performed followed by analysis of the relevant PEX gene. Occasionally,
cultured ﬁbroblasts studies show not any biochemical phenotype that
can be used for complementation studies. This has been reported in
peroxisomal mosaicism and/or in individuals with a milder phenotype
[41]. If a SPOD has been established, the nature of the enzymatic defectneeds to be determined using direct enzyme assays for acyl-CoA oxi-
dase, DBP and the peroxisomal thiolases followedbymolecular analysis.
3.2. RCDP spectrum
RCDP is biochemically characterized by plasmalogen deﬁciency and
normal VLCFA. If a patient is suspected to be affected by RCDP, either the
classical or variant phenotype, erythrocyte plasmalogens should be
determined. The ﬁnding of deﬁcient plasmalogens implies that the
patient is affected by a form of RCDP, either type 1 (PEX7 defect), type
2 or type 3 (Table 1). This can be further studied by detailed analysis
in ﬁbroblasts, which involves a series of enzymatic studies including
determination of DHAPAT and alkylDHAP synthase activities, phytanic
acidα-oxidaton, and phytanoyl-CoA hydroxylase activitymeasurement
and de novo plasmalogens biosynthesis. Finally, molecular genetic
testing is used to identify the exact molecular basis of the disease.
3.3. X-ALD/AMN complex
If the diagnosis is suspected in amale patient, plasmaVLCFAs should
be analyzed which is a very reliable marker to conﬁrm the diagnosis
with only one or two exceptions reported in literature. If abnormal,
X-ALD/AMN is virtually established and can be followed by mutation
analysis of the ABCD1 gene. If a female is suspected with X-ALD in its
heterozygote form, the diagnostic test of choice is mutation analysis of
the ABCD1 gene, because 15% of woman with X-ALD have normal
VLCFAs in plasma/serum [29].
3.4. The remaining disorders
3.4.1. Refsum disease
Plasma phytanic acid levels are always abnormal. Deﬁnite diagnosis
requires measurements of phytanoyl-CoA hydroxylase in ﬁbroblasts
followed by molecular genetic testing. Fewer than 10% of patients
with Refsum disease have a deﬁciency of the peroxisome targeting
signal type 2 (PTS2) receptor encoded by PEX7 [42].
3.4.2. Alpha-methylacyl-CoA racemace deﬁciency
The enzyme plays a role in the breakdown of pristanic acid and the
C27-bile acid intermediates DHCA and THCA. As a consequence, both
pristanic acid and phytanic acid accumulate with pristanic acid concen-
trationsmuchmore elevated than plasmaphytanic acid. After screening
the metabolites in the plasma, ﬁbroblast studies and molecular genetic
testing should be performed.
3.4.3. Peroxisomal sterol carrier protein X
The last step of the peroxisomal ß-oxidation process, thiolytic
cleavage, is performedby SCPx in the case of branched-chain substrates.
The patient reported by Ferdinandusse et al. presented marked
increased plasma pristanic acid, slightly increased plasma phytanic
acid, whereas the level of the straight-chain fatty acid C26:0 was just
above the highest value of the normal range [18]. Traces of the bile
acid intermediates DHCA and THCA were detected in both plasma and
urine. To establish the SCPx defect further ﬁbroblast analysis and
mutation analysis should be performed.
4. Discussion
Patients with peroxisomal disorders may have multiple organ
system dysfunction including failure to thrive, hearing and visual loss,
seizures and encephalopathy. The neurological disease in peroxisomal
disorders has wide phenotypic variation and can present with static
or progressive encephalopathy but may be suspected on the basis of
neuroimaging ﬁndings.
The diagnosis of peroxisomal disorders can be determined by
biochemical assays in blood and/or urine, followed by analysis in
Fig. 7. Axial T2-weighted image of a Zellweger spectrum patient with an “adult onset”
leukoencephalopathy at age 25 years with central cerebellar white matter lesions, includ-
ing the hilar region surrounding the dentate nucleus.
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severe classical ZS are severely hypotonic from birth on and have
characteristic facies, periarticular calciﬁcations, hepatic dysfunction,
severe brain dysfunction associated with neuronal migration disorder,
and usually die during the ﬁrst year of life. The diagnosis should be
straight forward as in the case of a patientwith the characteristic clinical
features of RCDP with symmetric proximal shortening of the humerus
with other skeletal abnormalities and congenital cataracts
In the absence of such distinct clinical presentations, cerebral MRI is
often a valuable tool in the diagnostic workup of patients with peroxi-
somal disorders and neurological disease [6,9,12,13,15,22,26,27,33].
Magnetic resonance imaging studies in peroxisomal disorders may
identify a number of rather characteristic patterns, including: (1) The
pattern of developmental anomalies including neocortical dysplasia
often shown by MRI adjoining an abnormal deep central sulcus
(Fig. 1) and non-speciﬁc myelination delay of the supratentorial white
matter; typical aspects of ZS and not constantly present in NALD and
isolateddisorders of peroxisomal ß-oxidation. (2) The pattern of regres-
sive changes of the white matter involving the central cerebellar area
and the hilus of the dentate nucleus. The ZSDs with a relatively longer
survival with symptomatic or asymptomatic leukoencephalopathy
may present this pattern as an early focus of whitematter involvement.
(3) The X-ALD pattern of white matter involvement. (4) The pattern of
abnormal parieto-occipital white matter with progressive cerebellar
atrophy, as seen in RCDP. (5) The pattern of T2-weighted increased
signal in thalamus, the pons and cerebral peduncles which can be
seen in AMACR deﬁciency.
The combination of the described neonatal or childhood clinical pro-
ﬁle in a patient and neocortical dysplasia as developmental abnormality
onMRI raises suspicion of one of the ZSDs or DBP deﬁciency. Neocortical
dysplasia, most frequently observed in the perisylvic region, is always
present in classical ZS. A typical combination of MRI abnormalities in
patients with a severe peroxisomal phenotype is generalized brain
atrophy and neocortical dysplasia characterized most frequently byperisylvic polymicrogyria and frontoparietal pachygyria [15] Clinical
details should be used for the differential diagnosis, and in some cases
other investigations thanMRImust lead to the right diagnosis. Leukoen-
cephalopathy is themost common ﬁnding in ZSD patients with a longer
course of disease and even in patientswith an onset of the leukoencepha-
lopathy not before adulthood. Striking central cerebellar white matter
lesions are then seen as an early focus (Fig. 7). This ﬁnding is often also
seen in cerebrotendinous xanthomatosis, a disease caused by storage of
bile alcohols [43]. In this context it seems noteworthy to mention that
toxic peroxisomal bile acids (precursors), i.e. DHCA and THCA, are present
in ZSDs. Patients with AMACR deﬁciency with accumulation of pristanic
acid, DHCA and THCA present an unusual MRI pattern for a peroxisomal
disorder. The pathogenetic mechanism of the abnormalities in pons,
basal ganglia and cerebral peduncles are largely unclear.
The pattern of developmental abnormalities onMRI in DBP deﬁcien-
cy, may be similar to that observed in the severe phenotype of the ZSD
[9], as well as cerebral and cerebellar demyelination in PBD patients
with prolonged survival [12,22]. The MRI pattern in the severe pheno-
type of RCDP is characterized by progressive signal abnormalities in
the parieto-occipital region and cerebellar atrophy [33]. The typical
pattern of demyelination starting in the occipital region and spreading
forwards is the characteristic hallmark for cerebral ALD [6].
Males with childhood onset of white matter disease and increased
VLCFAs in plasma will be diagnosed as an X-ALD. However, in the case
of clinical onset before 3 years of age or in case of not the typical MRI
pattern of cerebral X-ALD, but instead an early central cerebellar in-
volvement, additional peroxisomal investigations should be performed
to differentiate between X-ALD and PBD related white matter disease.
Early cerebellar white matter involvement is not seen in X-ALD, but
may be observed in PBD, especially in patients with the late onset white
matter phenotype [13].
We conclude that delineation of brain MRI abnormalities in the
various peroxisomal disorders with neurological disease is a tool for
analysing brain involvement in these diseases. MRI ﬁndings evolve
gradually during disease course and typical patterns can be observed.
It is essential to collect the natural course of MRI changes in relation
to clinical ﬁndings in order to learn about the disease process.References
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